Taysha Gene Therapies (NASDAQ:TSHA) Issues Earnings Results

Taysha Gene Therapies (NASDAQ:TSHA) issued its quarterly earnings data on Wednesday. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01, Zacks reports. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The company had revenue of $2.02 million during the quarter, compared to analysts’ expectations of $2.05 million.

Taysha Gene Therapies Price Performance

TSHA stock traded up $0.01 on Thursday, reaching $1.63. 123,039 shares of the company’s stock were exchanged, compared to its average volume of 2,057,802. The stock has a fifty day moving average of $1.68 and a 200-day moving average of $1.98. Taysha Gene Therapies has a twelve month low of $1.19 and a twelve month high of $4.32. The firm has a market cap of $333.03 million, a PE ratio of 2.58 and a beta of 0.93. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on TSHA shares. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday. Canaccord Genuity Group boosted their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a report on Friday, November 15th. JMP Securities reissued a “market outperform” rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Chardan Capital reissued a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Wednesday. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Taysha Gene Therapies presently has an average rating of “Buy” and an average target price of $6.63.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.